Identification

Name
Spectinomycin
Accession Number
DB00919  (APRD01232)
Type
Small Molecule
Groups
Approved, Investigational, Vet Approved
Description

An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.

Structure
Thumb
Synonyms
  • Actinospectacina
  • Espectinomicina
  • SCM
  • Spectinomicina
  • Spectinomycine
  • Spectinomycinum
External IDs
Antibiotic 2233wp / CHX-3101
Product Ingredients
IngredientUNIICASInChI Key
Spectinomycin dihydrochloride pentahydrateNot AvailableNot AvailableNot applicable
Spectinomycin hydrochlorideHWT06H303Z22189-32-8BIPVCOUVVAMJMZ-MTTMTQIXSA-N
Spectinomycin hydrochloride pentahydrateNot AvailableNot AvailableNot applicable
Spectinomycin sulfateBZ0H4TLF9X23312-56-3XGBFWQUQYQIFLB-MTTMTQIXSA-N
Spectinomycin sulfate tetrahydrateYS91P5491864058-48-6OBZDRKHRQYPQDZ-SACNDDTHSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Trobicin Inj 400mg/mlPowder, for solution400 mgIntramuscularUpjohn1972-12-311997-08-28Canada
International/Other Brands
Actinospectacin / Spectam / Togamycin / Trobicin
Categories
UNII
93AKI1U6QF
CAS number
1695-77-8
Weight
Average: 332.3496
Monoisotopic: 332.158351132
Chemical Formula
C14H24N2O7
InChI Key
UNFWWIHTNXNPBV-WXKVUWSESA-N
InChI
InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1
IUPAC Name
(1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.0³,⁸]tetradecan-7-one
SMILES

Pharmacology

Indication

For use in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of Neisseria gonorrhoeae.

Structured Indications
Not Available
Pharmacodynamics

Spectinomycin is an aminocyclitol antibiotic produced by a species of soil microorganism designated as Streptomyces spectabilis. In vitro studies have shown spectinomycin to be active against most strains of Neisseria gonorrhoeae (minimum inhibitory concentration <7.5 to 20 mcg/mL). Footprint studies indicate that spectinomycin exerts regional effects on ribosomal structure.

Mechanism of action

Spectinomycin is an inhibitor of protein synthesis in the bacterial cell; the site of action is the 30S ribosomal subunit. It is bactericidal in its action.

TargetActionsOrganism
A30S ribosomal protein S12
inhibitor
Escherichia coli (strain K12)
Absorption

Rapidly and almost completely absorbed after intramuscular injection.

Volume of distribution
Not Available
Protein binding

Not significant

Metabolism
Not Available
Route of elimination
Not Available
Half life

1 to 3 hours in patients with normal renal function and 10 to 30 hours in patients with impaired renal function with a creatinine clearance < 20 mL per minute.

Clearance
Not Available
Toxicity

Acute oral toxicity (LD50): >5000 mg/kg [Rat]. Information on overdosage in humans is not available.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategory
Spectinomycin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Experimental, Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Spectinomycin.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Spectinomycin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumSpectinomycin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidSpectinomycin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Spectinomycin can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmoxicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Spectinomycin.Approved, Investigational
AmpicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumSpectinomycin may increase the respiratory depressant activities of Atracurium.Experimental, Investigational
Atracurium besylateSpectinomycin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Spectinomycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Spectinomycin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Bacampicillin.Approved, Investigational
BalsalazideBalsalazide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Spectinomycin.Investigational
BendazacBendazac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzydamineBenzydamine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
BenzylpenicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Spectinomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
Botulinum Toxin Type ASpectinomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BSpectinomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Spectinomycin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Spectinomycin.Approved
CarbenicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Spectinomycin can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinSpectinomycin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Spectinomycin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
CisatracuriumSpectinomycin may increase the respiratory depressant activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateSpectinomycin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Spectinomycin.Approved
Clodronic AcidSpectinomycin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Spectinomycin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateSpectinomycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Spectinomycin can be decreased when it is combined with Cyclacillin.Approved
CyclosporineSpectinomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Spectinomycin.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
DecamethoniumSpectinomycin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Spectinomycin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Spectinomycin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Spectinomycin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Spectinomycin.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Spectinomycin.Approved
Domoic AcidSpectinomycin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideSpectinomycin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
EpicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Spectinomycin.Approved
EtanerceptEtanercept may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
Etidronic acidSpectinomycin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
EtoricoxibEtoricoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
exisulindexisulind may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Spectinomycin can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunixinFlunixin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Spectinomycin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Spectinomycin.Approved, Vet Approved
GallamineSpectinomycin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideSpectinomycin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Spectinomycin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
HigenamineHigenamine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
IbandronateSpectinomycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Spectinomycin.Experimental
LeflunomideLeflunomide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Spectinomycin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
MecamylamineSpectinomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational, Withdrawn
MetampicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of Spectinomycin can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Spectinomycin.Experimental
MetocurineSpectinomycin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideSpectinomycin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Spectinomycin can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumSpectinomycin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Spectinomycin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinSpectinomycin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Spectinomycin.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Spectinomycin.Approved
OxacillinThe serum concentration of Spectinomycin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Withdrawn
PamidronateSpectinomycin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumSpectinomycin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of Spectinomycin can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of Spectinomycin can be decreased when it is combined with Penimepicycline.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Spectinomycin.Experimental
PhenoxymethylpenicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Spectinomycin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
PipecuroniumSpectinomycin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Spectinomycin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Spectinomycin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Spectinomycin can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental, Investigational
Procaine benzylpenicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Spectinomycin.Experimental
PTC299PTC299 may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
PyrantelSpectinomycin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumSpectinomycin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Experimental, Investigational
RisedronateSpectinomycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumSpectinomycin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
SuccinylcholineSpectinomycin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Spectinomycin can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Spectinomycin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
TazobactamThe serum concentration of Spectinomycin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateSpectinomycin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateSpectinomycin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Spectinomycin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Spectinomycin can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidSpectinomycin may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Spectinomycin.Approved
TranilastTranilast may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational
TubocurarineSpectinomycin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Spectinomycin.Approved
VecuroniumSpectinomycin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational
ZileutonZileuton may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidSpectinomycin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

David R. White, "Intermediate compounds in the preparation of spectinomycin." U.S. Patent US4344882, issued August, 1966.

US4344882
General References
Not Available
External Links
Human Metabolome Database
HMDB15055
KEGG Compound
C02078
PubChem Compound
15541
PubChem Substance
46505032
ChemSpider
14785
ChEBI
9215
ChEMBL
CHEMBL1167
Therapeutic Targets Database
DAP000403
PharmGKB
PA164781342
HET
SCM
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Spectinomycin
ATC Codes
J01XX04 — Spectinomycin
PDB Entries
1fjg / 4v56 / 4v57
MSDS
Download (24.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
Not AvailableCompletedTreatmentLabour / Lumbar epidural anesthesia1

Pharmacoeconomics

Manufacturers
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionIntramuscular400 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityEasily soluble in cold waterNot Available
logP-2.3Not Available
pKa6.95MERCK INDEX (1996); pKa1
Predicted Properties
PropertyValueSource
Water Solubility150.0 mg/mLALOGPS
logP-1.4ALOGPS
logP-2.4ChemAxon
logS-0.35ALOGPS
pKa (Strongest Acidic)8.58ChemAxon
pKa (Strongest Basic)9.4ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area129.51 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity75.44 m3·mol-1ChemAxon
Polarizability33.39 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7118
Blood Brain Barrier-0.9892
Caco-2 permeable-0.6803
P-glycoprotein substrateNon-substrate0.526
P-glycoprotein inhibitor INon-inhibitor0.6468
P-glycoprotein inhibitor IINon-inhibitor0.9228
Renal organic cation transporterNon-inhibitor0.9646
CYP450 2C9 substrateNon-substrate0.7711
CYP450 2D6 substrateNon-substrate0.8496
CYP450 3A4 substrateNon-substrate0.5056
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9182
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8434
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9254
Ames testNon AMES toxic0.7167
CarcinogenicityNon-carcinogens0.9602
BiodegradationNot ready biodegradable0.983
Rat acute toxicity1.8538 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.996
hERG inhibition (predictor II)Non-inhibitor0.9493
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-08fr-0981000000-7b067e918b209eac92b8
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0009000000-b9eac7fc0b26b25322e5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0109000000-579b95f7f98de34557b5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-1905000000-2a7f6f7210597e02ca8b
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0005-8900000000-cbcc3a787f8ddb194a17
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00dj-9200000000-8e0fffdf1e10bf82d5f6
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-000i-0931000000-72bf96c01e6ac30e14de
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-000i-0963000000-2806611756fc50c1eada

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,4-dioxanes. These are organic compounds containing 1,4-dioxane, an aliphatic six-member ring with two oxygen atoms in ring positions 1 and 4.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Dioxanes
Sub Class
1,4-dioxanes
Direct Parent
1,4-dioxanes
Alternative Parents
Oxanes / Secondary alcohols / Ketones / Hemiacetals / Cyclic alcohols and derivatives / 1,2-aminoalcohols / Polyols / Oxacyclic compounds / Dialkylamines / Acetals
show 3 more
Substituents
Para-dioxane / Oxane / Cyclic alcohol / 1,2-aminoalcohol / Secondary alcohol / Hemiacetal / Ketone / Acetal / Secondary aliphatic amine / Oxacycle
show 13 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
cyclic ketone, organic heterotricyclic compound, secondary amino compound, cyclic hemiketal, cyclic acetal (CHEBI:9215) / Actinamines (C02078)

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Lo...
Gene Name
rpsL
Uniprot ID
P0A7S3
Uniprot Name
30S ribosomal protein S12
Molecular Weight
13736.995 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Yamagata H, Dombou M, Sato T, Mizushima S, Uchida H: Deletion mapping and heterogenote analysis of a mutation responsible for osmosis-sensitive growth, spectinomycin resistance, and alteration of cytoplasmic membrane in Escherichia coli. J Bacteriol. 1980 Aug;143(2):661-7. [PubMed:6451613]
  4. Gordeev VK, Turkov MI: [Functioning of amino acid operons in Escherichia coli strains with an altered transcription and translation apparatus. II. The effect of mutations in genes coding ribosomal protein S5 and translation elongation factor G on the functioning of the ilv operon]. Genetika. 1983;19(2):217-20. [PubMed:6339322]
  5. Eisenstein BI, Beachey EH, Ofek I: Influence of sublethal concentrations of antibiotics on the expression of the mannose-specific ligand of Escherichia coli. Infect Immun. 1980 Apr;28(1):154-9. [PubMed:6103875]
  6. Carter AP, Clemons WM, Brodersen DE, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V: Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8. [PubMed:11014183]

Drug created on June 13, 2005 07:24 / Updated on December 13, 2017 10:17